Shilpa Medicare is currently trading at Rs. 821.05, up by 15.15 points or 1.88% from its previous closing of Rs. 805.90 on the BSE.
The scrip opened at Rs. 806.05 and has touched a high and low of Rs. 831.15 and Rs. 802.50 respectively. So far 13292 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 959.95 on 18-Sep-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023.
Last one week high and low of the scrip stood at Rs. 838.85 and Rs. 793.60 respectively. The current market cap of the company is Rs. 7988.54 crore.
The promoters holding in the company stood at 44.39%, while Institutions and Non-Institutions held 16.69% and 38.92% respectively.
Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin.
Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Desmopressin helps to reduce frequent urination and excessive thirst. This is used to treat central diabetes insipidus and bedwetting.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |